RAPT Therapeutics (NASDAQ:RAPT) Cut to Neutral at HC Wainwright

HC Wainwright downgraded shares of RAPT Therapeutics (NASDAQ:RAPT – Free Report) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, Marketbeat reports. Several other research firms have also recently commented on RAPT. JPMorgan Chase & Co. increased their target price on RAPT Therapeutics from $32.00 to […]

Related Keywords

United States , ,Tower Research Capital ,Wolfe Research ,Securities Exchange Commission ,Northern Trust Corp ,Therapeutics Company Profile ,Therapeutics Inc ,Group Plc ,Manufacturers Life Insurance Company ,Cantor Fitzgerald ,Jpmorgan Chase Co ,Free Report ,Moderate Buy ,Trading Down ,Exchange Commission ,Research Capital ,Trust Corp ,General Group Plc ,Get Free Report ,Rapt Therapeutics ,Nasdaq Rapt ,Strapt ,Medical ,Downgrade ,Hc Wainwright ,